A new paradigm for cancer treatment
Excellamol is producing polypeptide-drug conjugates that directly target the tumor microenvironment.
Self-Depot Platform
Excellamol’s Self-Depot platform comprises polypeptide-drug conjugates, polypeptide-cytokine fusions, and polypeptide-stem cell composites.
